Biochemical Amenability in Fabry Patients Under Chaperone Therapy—How and When to Test?
BioDrugs · 2024
DOI: 10.1007/s40259-024-00678-x ↗Kurz gefasst
Fachartikel in der Zeitschrift BioDrugs, 2024. Verfasst von Malte Lenders und 2 weiteren Autor:innen. Beteiligte Einrichtung: Internal Medicine D (Nephrology, Hypertension and Rheumatology), and Interdisciplinary Fabry Center (IFAZ), University Hospital Muenster, Albert-Schw…. Hauptthemen laut MEDLINE: Fabry Disease, alpha-Galactosidase, 1-Deoxynojirimycin. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Open Access funding enabled and organized by Projekt DEAL..
Abstract (Originalsprache)
AIM: Current recommendations for Fabry disease include α-galactosidase A (AGAL) activity measurements to assess the biochemical response in migalastat-treated patients. Owing to contradictory data from laboratories, we aimed to analyze why AGAL activity measures from dried blood spots (DBS) often fail to detect migalastat-mediated enzymatic activity increases in treated patients. METHODS: 43 patients with 58 visits under migalastat were consecutively recruited. Enzymatic AGAL activities were measured from DBS and peripheral blood mononuclear cells (PBMCs). Migalastat concentrations in sera were determined using modified serum-mediated inhibition assays to assess Cmax and serum half-life. Results were set in relation to the time of last migalastat intake and blood sampling to assess an optimal timepoint for AGAL activity measures. RESULTS: DBS-based AGAL activity measurements of 21 (42.0%) amenable patients were below the limit of detection. Serum samples from migalastat-treated patients showed significant AGAL inhibition, depending on the time between migalastat intake and blood sampling (r2 = 0.8140, p < 0.0001). Migalastat concentrations were determined in serum samples confirming a Cmax at 3 h and a serum half-life of 4 h. At 24 h after intake, migalastat clearance was significantly associated with renal function (r2 = 0.3135, p = 0.0102). Enzymatic AGAL activities were higher in samples from DBS and PBMCs 24 h after migalastat intake (both p < 0.05). CONCLUSION: The optimal time for enzymatic AGAL activity measurement in migalastat-treated patients appears to be 24 h after the last migalastat intake. Since migalastat is a competitive inhibitor of AGAL, enzymatic AGAL activity measurements should be better performed from PBMCs to reduce migalastat-mediated interferences.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Internal Medicine D (Nephrology, Hypertension and Rheumatology), and Interdisciplinary Fabry Center (IFAZ), University Hospital Muenster, Albert-Schweitzer-Campus 1, 48149, Muenster, Germany. Malte.Lenders@ukmuenster.de.
- Internal Medicine D (Nephrology, Hypertension and Rheumatology), and Interdisciplinary Fabry Center (IFAZ), University Hospital Muenster, Albert-Schweitzer-Campus 1, 48149, Muenster, Germany.
Förderung
- Open Access funding enabled and organized by Projekt DEAL.
Zitieren
APA
Lenders, M., Menke, E. R., & Brand, E. (2024). Biochemical Amenability in Fabry Patients Under Chaperone Therapy—How and When to Test?. BioDrugs. https://doi.org/10.1007/s40259-024-00678-x
Vancouver
Lenders M, Menke ER, Brand E. Biochemical Amenability in Fabry Patients Under Chaperone Therapy—How and When to Test?. BioDrugs. 2024. doi:10.1007/s40259-024-00678-x
BibTeX
@article{Lenders2024,
author = {Lenders, Malte and Menke, Elise Raphaela and Brand, Eva},
title = {Biochemical Amenability in Fabry Patients Under Chaperone Therapy—How and When to Test?},
journal = {BioDrugs},
year = {2024},
doi = {10.1007/s40259-024-00678-x}
}
EUVIMED